The slowdown in China, with its accompanying decline in imports, is hurting U.S. manufacturers, especially those that have 50% of their sales growth tied to China, said Yingying Xu, director of economic studies at MAPI. "China's economic re-balance is going to take some time, not one or two years but four, five years," Xu said.
The Federal Reserve reported that U.S. manufacturing output rose in May, numbers that confirm earlier indications that the sector is doing well, says Daniel Meckstroth, chief economist for MAPI. "Growth is driven by a ramping-up of the housing supply chain, a rebuilding of transportation equipment infrastructure, strong growth in oil and gas infrastructure, and pent-up demand for factory machinery," Meckstroth says.
Finox Biotech was founded late in 2007 as a virtual company and has made considerable progress in developing its first biosimilar, Afolia, a recombinant-human follicle-stimulating hormone. In this article, the first part of two, the co-founder and CEO of Finox Biotech describes in detail the company's target selection and approach to choosing the right partners. Check back next week for Part II.